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Chronic g-secretase inhibition reduces amyloid plaque-associated
instability of pre- and postsynaptic structures
S Liebscher1,2, RM Page2, K Ka¨fer1, E Winkler2, K Quinn3, E Goldbach3, EF Brigham3, D Quincy3, GS Basi3, DB Schenk4, H Steiner2,5,
T Bonhoeffer1, C Haass2,5,6, M Meyer-Luehmann2,7,8 and M Hu¨bener1,7
The loss of synapses is a strong histological correlate of the cognitive decline in Alzheimer’s disease (AD). Amyloid bpeptide (Ab),
a cleavage product of the amyloid precursor protein (APP), exerts detrimental effects on synapses, a process thought to be causally
related to the cognitive deﬁcits in AD. Here, we used in vivo two-photon microscopy to characterize the dynamics of axonal
boutons and dendritic spines in APP/Presenilin 1 (APPswe/PS1L166P)–green ﬂuorescent protein (GFP) transgenic mice. Time-lapse
imaging over 4 weeks revealed a pronounced, concerted instability of pre- and postsynaptic structures within the vicinity of
amyloid plaques. Treatment with a novel sulfonamide-type g-secretase inhibitor (GSI) attenuated the formation and growth of new
plaques and, most importantly, led to a normalization of the enhanced dynamics of synaptic structures close to plaques. GSI
treatment did neither affect spines and boutons distant from plaques in amyloid precursor protein/presenilin 1-GFP (APPPS1-GFP)
nor those in GFP-control mice, suggesting no obvious neuropathological side effects of the drug.
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INTRODUCTION
Alzheimer’s disease (AD) is characterized by a progressive decline
of memory function and cognition. Hallmarks of AD pathology are
extracellular aggregates of the amyloid b-peptide (Ab), so-called
amyloid plaques, and neuroﬁbrillary tangles, which represent
intraneuronal aggregates of hyperphosphorylated tau protein. The
strongest correlate of the cognitive decline seen in AD, however, is
the loss of synapses.1–3 Moreover, there is mounting evidence for
synaptic dysfunction and failure in AD both in vitro and in vivo
(reviewed by Kofﬁe et al.4 and Selkoe5). Oligomeric Ab, as one of
the key factors in AD,4–7 is known to colocalize with dendritic
spines—the main sites of synaptic input to excitatory pyramidal
neurons—potentially binding to molecular components of the
postsynapse,8–10 and thereby exhibiting deleterious effects on
dendritic spines.4,7,11 This negative impact of Ab on dendritic
spines is most pronounced in close vicinity to amyloid plaques,
causing an impairment of spine stability, which is thought to result
in the loss of spines12–15 and ultimately synaptic connections.
Previous in vivo imaging studies have largely focused on the
impact of amyloid plaques on dendritic spines,15,16 whereas not
much is known about the presynaptic side, namely axonal boutons,
in vivo. Histological studies, mostly using presynaptic markers,
reported an overall decrease in synaptic density in AD patients,1,2
whereas only a local reduction of presynaptic marker density close to
plaques was observed in amyloid precursor protein (APP) transgenic
mice.17–19 Given the described effect of Ab on the dynamics and
density of dendritic spines, we hypothesized that these amyloid
plaque-associated postsynaptic alterations should be paralleled by
changes of the presynaptic compartment, either directly caused by
the plaque itself or secondary to changes of spines.
In the current study, we thus used in vivo two-photon imaging
to follow dendritic spines and axonal boutons over the course of
several weeks in wild-type (WT) and amyloid precursor protein/
presenilin 1 (APPPS1) mice. We found an enhanced instability of
both, pre- and postsynaptic structures, seen, for example, as a
higher turnover rate and a lower survival fraction, limited to the
immediate vicinity of plaques.
We then investigated whether these pathologically increased
synaptic dynamics can be reduced or halted by treatment
targeting Ab generation. As Ab is liberated upon sequential
cleavage of APP by the b- and g-secretase,6,20 pharmacological
inhibition of g-secretase represents one way to interfere with Ab
generation. Although g-secretase inhibitors (GSIs) have been
shown to efﬁciently lower Ab levels in the central nervous system
(CNS) and reduce amyloid plaque load in animal models of the
disease,21,22 little is known about their potential to prevent
plaque-associated synapse pathology.
We thus applied the novel, selective GSI (ELN594) daily for 4
weeks, and monitored plaque progression and associated
dendritic spine and axonal bouton pathology in APPPS1 mice.
GSI treatment reduced de novo plaque formation after the ﬁrst
week of treatment, slowed down the growth of these newly
deposited plaques and, importantly, stabilized spines near plaques
by lowering their turnover rate and increasing their survival
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fraction. Likewise, GSI treatment normalized the survival fraction
of boutons near plaques. Spines and boutons further away from
plaques in APPPS1 mice and in WT mice were not affected by the
GSI treatment.
MATERIALS AND METHODS
Animals for in vivo imaging experiments
For chronic in vivo imaging experiments, APPPS1þ / transgenic mice
(co-expressing APP containing the Swedish double-mutation KM670/
671NL and PS1 containing the L166P mutation under the Thy-1
promoter)23 were crossbred with green ﬂuorescent protein (GFP)-Mþ /þ
transgenic mice (expressing EGFP under the Thy-1 promoter, causing
sparse labeling of mainly cortical layer V pyramidal neurons).24 Animals
were kept under a 12/12-h light–dark cycle with food and water ad libitum
and housed individually on standard cage bedding, without additional
nesting material. All animal procedures followed a protocol approved by
the local authorities (Regierung von Oberbayern). For imaging experi-
ments, only male mice were used.
Drug administration
Male mice were treated with ELN594 (Elan Pharmaceuticals, South San
Francisco, CA, USA (see synthesis approach25)) at the age of 3–4 months.
The drug, dissolved in 2% methyl cellulose and 0.5% Tween20, was
administered daily for four subsequent weeks via oral gavage at
30mg kg 1. All control mice received vehicle solution (2% methyl
cellulose and 0.5% Tween20) only. Treatment started immediately after
the ﬁrst imaging session.
In vivo imaging
In brief, 4 weeks after implantation of a cranial window spanning both
hemispheres (coordinates of craniotomy: Bregma þ 1.5– 3.5mm, 3mm
lateral from midline on each side) the apical tufts of GFP-expressing layer V
pyramidal neurons and axonal boutons of layer II/III/V neurons, as well as
amyloid plaques were repeatedly imaged at 7-day intervals. Amyloid
plaques were stained by intraperitoneal injection of the dye Methoxy-XO4
(Neuroptix Corporation) 24 h prior to every imaging session.
Details on drug characterization, cranial window surgery, imaging, data
analysis and statistics are provided in Supplementary Materials and
Methods.
RESULTS
In order to characterize the impact of amyloid plaque pathology
on the dynamics of synaptic structures in vivo, we performed
longitudinal in vivo two-photon imaging in male WT and APPPS1
mice (Supplementary Figure S1). We then assessed whether
pharmacological interference with Ab generation exerts beneﬁcial
effects on plaque-associated synaptic pathology in APPPS1 mice.
To this end, we administered the selective GSI, ELN594 (see
Supplementary Results), daily (30mg kg 1), for 4 consecutive
weeks to WT and APPPS1 mice at the ages of 3–4 months and
monitored amyloid pathology, dendritic spines and axonal
boutons in vivo throughout the treatment period.
Amyloid plaque-associated spine pathology
As there is accumulating evidence that plaques cause neuritic and
spine pathology predominantly within 50mm distance to pla-
ques,12,14–16,26,27 we analyzed dendritic spines on apical tufts of
layer V pyramidal neurons in WT (Figure 1a) and APPPS1 mice in
the immediate vicinity of plaques (o50mm, ‘near’; Figure 1b)
and further away (450mm, ‘distant’). As described before13,15,16
(for review see Liebscher and Meyer-Luehmann28), we found that
dendritic stretches within the immediate vicinity of amyloid
plaques exhibited a lower spine density (average over all time
points 0.22±0.017mm 1) compared with stretches further away
from plaques in APPPS1 (0.28±0.013mm 1) and WT mice
(0.29±0.017mm 1, Figure 1c). A more detailed analysis revealed
that spine density was signiﬁcantly reduced up to 15mm from the
plaque border compared with the spine density of WT vehicle-
treated mice13,15 (Supplementary Figure S2a) and that spine
density was positively correlated with plaque distance up to
50mm away from the plaque border (Pearson’s correlation
coefﬁcient r¼ 0.23, P¼ 0.01). The drop in spine density near
plaques did not depend on plaque size (r¼  0.05, P¼ 0.56;
Supplementary Figure S2a).
Determining spine density alone is insufﬁcient to capture all
aspects of potential (pathological) spine alterations, as they are
dynamic structures, which are lost and gained at a certain rate,
even under baseline conditions.29–32 We hence determined the
spine survival fraction and turnover rate and classiﬁed spines,
according to their lifetime, as persistent or transient (Figure 1e).
Spines close to plaques are less stable, which is reﬂected in a
lower survival fraction (Figure 1d), a lower fraction of persistent
spines compared with spines distant from plaques and in WT
mice (Figure 1f) and, accordingly, a higher fraction of transient
spines (Figure 1f). The high turnover rate of spines near plaques
(Figure 1g) resulted from both an increased elimination (Figure 1h)
and formation rate (Figure 1i). The elevated spine turnover did
neither depend on plaque proximity within a 50 mm radius to the
plaque border (r¼ 0.04, P¼ 0.79) nor on plaque size (r¼  0.09,
P¼ 0.51, Supplementary Figure S2b).
There was no signiﬁcant difference between spines in WT mice
and spines further away from plaques in APPPS1 mice for any of
the spine parameters analyzed. A more detailed analysis, however,
revealed a negative correlation between turnover rate and spine
density in WT mice in line with a previous publication.30
Interestingly, this correlation was positive for dendrites further
away from plaques in APPPS1 mice (WT: r¼  0.52, P¼ 0.039;
APPPS1: r¼ 0.47, P¼ 0.025; Supplementary Figure S3a). This
difference was largely due to dendritic stretches with a low spine
density (0.15–0.26mm 1), which exhibited a signiﬁcantly lower
spine turnover rate in APPPS1 mice (Supplementary Figure 3b). The
absolute density of gained spines was independent of
the total spine density in WT mice (r¼ 0.011, P¼ 0.97,
Supplementary Figure 3c). In contrast, in APPPS1 mice, dendrites
distant from plaques exhibited a signiﬁcant positive correlation
between the density of gained spines and total spine density
(r¼ 0.73, Po0.001, Supplementary Figure 3c). Again low-density
dendrites (p0.26mm 1) in APPPS1 mice had a signiﬁcantly lower
density of newly formed spines in comparison with WT mice
(Supplementary Figure 3d). These data indicate a plaque-indepen-
dent effect on spine dynamics in APPPS1-transgenic mice, which
mainly affects dendritic stretches with a low spine density. We did
not observe a signiﬁcant correlation between spine density and
turnover rate for spines close to plaques (r¼  0.47, P¼ 0.12).
Amyloid plaque-associated axonal bouton pathology
Not much is known about the dynamics of plaque-associated
presynaptic structures. We therefore analyzed axonal boutons
located within the same imaged volumes as the above described
dendrites. We took advantage of the fact that bouton dynamics
were described in detail for the GFP-M mouse line in a recent
publication.33 Based on this study and judged by bouton size as
well as the number and length of axonal branches, the majority of
axons investigated are putatively originating from layer II/III/V cells
(Figures 2a and b). In addition to en passant boutons, which
represented the majority of boutons, terminaux boutons were
included in the analyses, as their fraction was low and did not
differ signiﬁcantly between groups (fraction terminaux boutons:
WT 0.04±0.065, APP distant 0.09±0.12, APP near 0.076±0.1,
Kruskal–Wallis, P¼ 0.45).
We did not ﬁnd a signiﬁcant difference in bouton density
between WT and APPPS1 mice (WT 0.12±0.01 mm 1, APP distant
0.12±0.01 mm 1, APP near 0.13±0.013 mm 1, Figure 2c).
Furthermore, on axonal stretches close to plaques, the
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Figure 1. Amyloid plaque-associated dendritic spine alterations. (a and b) Representative examples of apical dendritic stretches of layer V pyramidal
neurons repeatedly imaged within layer I over the course of 4 weeks in wild-type (WT) and amyloid precursor protein/presenilin 1 (APPPS1) mice
(shown are maximum projections). Note that the actual position of the dendritic stretch in panel b is just above the plaque, with the dendrite not
passing through it. Open arrowhead: spine lost, filled arrowhead: spine gained. (c) Spine density is significantly lower in the vicinity of plaques in
APPPS1 mice, compared with dendrites further away from plaques and WT mice, respectively (repeated measures analysis of variance (ANOVA);
Po0.001 and Po0.001). (d) Survival fraction of spines near plaques is significantly decreased (repeated measures ANOVA, Po0.001). (e)
Classification of spines with respect to their lifetime. Filled circles denote the presence of a spine at the respective time point, open circles
correspond to the absence of a spine and half-filled circles denote a spine being either present or absent at the respective time point. (f ) Dendrites
near plaques have fewer persistent (one-way ANOVA, Po0.01 and Po0.05) and more transient spines compared with spines distant from plaques
and in WT mice (one-way ANOVA, Po0.001 and Po0.01). (g) Spine turnover rates near plaques are significantly elevated compared with spines
further away from plaques and WT mice, respectively (one-way ANOVA, Po0.001). (h and i) Increased turnover results from higher (h) elimination
(one-way ANOVA, Po0.001 and Po0.01) and (i) formation rates (Kruskal–Wallis, Po0.001 and Po0.05). Data in panels g–i are average values over all
imaging time points. WT: n¼ 16 dendrites (four mice); APP distant: n¼ 21 dendrites (five mice); APP near: n¼ 12 dendrites (five mice). Values are
mean±s.e.m., scale bar 5mm (b), *Po0.05, **Po0.01, ***Po0.001.
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inter-bouton distance did also not depend on plaque proximity
(Supplementary Figure S4). However, similar to our data on
dendritic spines near plaques, the survival fraction of boutons near
plaques was decreased compared with boutons further away from
plaques and in WT mice (Figure 2d). Analysis of boutons with
different lifetimes did not yield a signiﬁcant difference between
axons in APPPS1 and WT mice (Figure 2e). However, boutons near
plaques exhibited a higher turnover rate compared with boutons
further away from plaques and boutons in WT mice (Figure 2f).
Separate analyses of elimination and formation rate showed the
same trend but did not reach signiﬁcance (Figures 2g and h).
Overall, boutons appeared less dynamic than spines on apical
tufts of layer V neurons, corroborating earlier reports.30,33 Newly
formed spines have been shown to preferentially target large
multisynaptic boutons,34 which could account for the observed
difference.
Apart from the above mentioned changes in bouton dynamics,
we occasionally observed the emergence of axonal dystrophies,
axonal breakage and axonal sprouting within the peri-plaque
region (Supplementary Figure S5). These structural alterations
Figure 2. Bouton dynamics in wild-type (WT) and amyloid precursor protein/presenilin 1 (APPPS1) mice. (a and b) Examples of axonal
stretches in (a) WT and (b) APPPS1 mice over the 4-week-imaging period are shown as maximum projections. Boutons lost from one time
point to the next are marked with open arrowheads, boutons gained with filled arrowheads. (c) Bouton density is not different between axons
near plaques, further away from plaques or in WTmice (repeated measures ANOVA, P¼ 0.93). (d) Boutons near plaques exhibit a lower survival
fraction (repeated measures ANOVA, Po0.01). (e) Bouton lifetime categories (see Figure 1e) do not differ significantly among groups (fraction
persistent boutons: one-way ANOVA, P¼ 0.12, fraction transient: Kruskal–Wallis P¼ 0.31, fraction persistent lost: Kruskal–Wallis P¼ 0.63,
fraction persistent gained: Kruskal–Wallis P¼ 0.61). (f ) Turnover rate is increased on boutons close to plaques (Kruskal–Wallis, Po0.05).
Separate analysis of (g) elimination and (h) formation rate showed the same trend but did not reach significance (Kruskal–Wallis, P¼ 0.23 and
P¼ 0.24). WT: n¼ 17 axons (four mice); APP distant: n¼ 14 axons (four mice); APP near: n¼ 13 axons (four mice). Values are mean±s.e.m., scale
bar 10 mm (b), *Po0.05, **Po0.01.
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occurred only rarely in APPPS1-GFP mice, probably attributable to
the young age of 3–4 months and the sparse labeling of neurons
in the GFP-M mouse line.
Initial reduction in de novo plaque deposition by GSI treatment
We next investigated whether the enhanced dynamics of synaptic
structures near amyloid plaques can be halted by Ab-targeting
treatment. For this purpose, we tested the sulfonamide-type GSI
ELN594 both in WT and APPPS1 mice.
ELN594 is an orally available, CNS penetrant and highly potent
GSI (see Supplementary Results, Supplementary Figures S6a–c). As
PS1 mutations of familial AD, such as the aggressive PS1L166P
mutation35 present in the mouse model used here, are known to
be less sensitive to GSIs,36 we ﬁrst tested the effect of a single
dose of ELN594 (30mg kg 1) on APP C-terminal fragments as well
as Ab40 and Ab42 levels in brains of APPPS1-GFP mice 24 h after
drug application. The GSI efﬁciently inhibited g-secretase as
shown by the pronounced accumulation of APP C-terminal
fragments in the western blot analysis (219% compared with
vehicle-treated animals, Figures 3a and b). In accordance with the
observed increase in APP C-terminal fragment levels, we found
that soluble Ab40 and Ab42 levels were signiﬁcantly decreased by
66% and 59%, respectively, upon GSI application, indicating that
GSI treatment efﬁciently lowers Ab levels in the APPPS1 mouse
model (Figure 3c).
We next analyzed the potential of the GSI to interfere with de
novo deposition of plaques using repeated two-photon imaging
(Figures 3d and e). We found that ELN594 affected plaque
formation, manifested as a drop in the number and size of newly
deposited plaques in GSI-treated APPPS1 mice compared with
vehicle-treated mice after the ﬁrst week of GSI treatment (Figures
3f and g). The observed decrease in newly formed plaques after 1
week of treatment ceased over the course of the experiment, and
a general decline in the occurrence of new plaques was seen in
both GSI-treated and control mice, which might reﬂect the age
dependency of plaque deposition (Figure 3f). However, plaques
newly formed within the ﬁrst week of treatment grew signiﬁcantly
slower in GSI compared with vehicle-treated mice, indicating a
sustained effect of the GSI throughout the treatment period
(Figure 3h).
Effect of GSI treatment on plaque-associated spine and bouton
alterations
We applied the GSI to APPPS1 mice daily for 4 consecutive weeks.
WT mice were treated in addition in order to test for potential
adverse effects of the treatment that have been described in a
previous publication for unselective GSIs of a different structural
class.37 GSI treatment had neither an effect on spine density in
APPPS1 (Figures 4a and b) nor on those in WT mice
(Supplementary Figure S7a) over the course of the 4-week
treatment period.
Importantly, GSI treatment counteracted the plaque-associated
changes in spine dynamics. More speciﬁcally, in GSI-treated mice
we found a higher spine survival fraction near plaques (Figure 4c),
a higher fraction of persistent spines (Figure 4d) and accordingly a
lower fraction of transient spines (Figure 4d) compared with
spines near plaques in vehicle-treated mice. The pathologically
enhanced elimination and formation rates of spines near plaques
in vehicle-treated mice were reduced by the GSI to levels found on
dendrites further away from plaques (Figures 4e–g). Note that
presented here are average values over all time points, as spine
dynamics were consistently elevated throughout the treatment
period (see Supplementary Figures S8a–c).
As the density of spines within a radius of 50mm to the
plaque edge correlates well with the effective plaque distance
(Supplementary Figure S2a), we investigated whether GSI treat-
ment affects spines in a distance-dependent manner. Whereas the
GSI had no effect on spine density near plaques at any given
distance between 0 and 50 mm, the turnover rate was signiﬁcantly
reduced for spines that were 415 mm (yet o50 mm) away from
the plaque border (Supplementary Figures S9a–d).
In addition to alterations in synapse number and turnover,
pathology might also be reﬂected in changes to the strength of a
synapse, which is known to correlate well with spine size.34,38,39
We hence determined integrated spine brightness as a measure
for spine size.31 In line with a previous report,40 the overall
distribution of spine sizes resembled a log-normal distribution,
both for spines close to plaques in APP and WT mice
(Supplementary Figures S10a–c). Average spine size as well as
spine-size distribution did not differ between treatment groups
(Supplementary Figures S10b–d).
As stable spines are considered the structural correlates of long-
term memories,41,42 we next performed the same analysis
separately for persistent spines. We determined their size
difference between the ﬁrst and the last imaging time point
(Supplementary Figure S10e). In line with our ﬁndings of higher
spine turnover rates in the vicinity of plaques, we observed a
signiﬁcantly higher fraction of persistent spines with a large size
change (difference in integrated brightness larger than the mean
difference±1.5 s.d. of persistent spine-size changes in WT
vehicle-treated mice) close to plaques (WT vehicle 15.4% versus
APP near vehicle 27.7%, Supplementary Figure S10f). GSI
treatment led to a reduction in this ‘large size change fraction’
of persistent spines (20.1%), which did not signiﬁcantly differ
anymore from WT vehicle mice (Supplementary Figure S10f).
GSI treatment did not affect spines further away from plaques
and in WT mice (for data on WT mice, see Supplementary Figures
S7a–d), indicating no obvious neuropathological side effect of the
GSI treatment.
Owing to the high variability, it was more difﬁcult to pinpoint
the impact of the GSI on bouton dynamics (Figure 5a), but overall
we found the same trend as for dendritic spines. Bouton density
was not signiﬁcantly affected by the GSI treatment, yet a trend
towards a decrease throughout the imaging period was observed
near plaques in vehicle-treated mice (Figure 5b). These ﬁndings
notwithstanding, we did observe a normalization of the bouton
survival fraction near plaques to levels found distant from plaques
(Figure 5c). The signiﬁcantly elevated bouton turnover rate near
plaques was somewhat decreased by the GSI; however, the effect
did not reach signiﬁcance (Figure 5d). The same held true for the
fraction of persistent boutons near plaques, where we observed a
nonsigniﬁcant increase after the GSI treatment (one-way ANOVA,
P¼ 0.22, Figure 5e).
In summary, our data demonstrate that the dynamics of both
the pre- and postsynaptic compartments is affected by the
amyloid plaque pathology. Moreover, we found that interference
with Ab generation by applying the GSI, ELN594, can attenuate
the plaque-associated instability of synaptic structures. ELN594
does neither affect spines or boutons further away from plaques in
APPPS1 nor those in WT mice, and hence seems to be devoid of
apparent neuropathological side effects.
DISCUSSION
In this study, we have used a longitudinal in vivo two-photon
imaging approach to characterize plaque-associated alterations of
pre- and postsynaptic structures in a mouse model of AD. We
demonstrate that interference with Ab generation, via the
application of a novel GSI, can counteract the plaque-associated
synaptic instability in vivo.
There is growing consensus that, for a treatment against AD to
be effective, it should commence already during the presympto-
matic phase of the disease.43 A number of studies performed in
APP-transgenic mice have revealed an intimate relationship
between amyloid plaques and structural/functional neuronal
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alterations.12–15,26,44 As these structural alterations are considered
a precursor to eventual neuronal death, characteristic for human
AD pathology,45 mouse models are well suited to study the
efﬁcacy of candidate drugs on these early neuropathological
changes.
Our results, similar to previous publications,12,15,16 show a lower
spine density and a pronounced spine instability within the
immediate vicinity of amyloid plaques. The observed increase in
spine turnover was attributable to almost equally enhanced spine
formation and elimination rates, thereby not resulting in a change
of spine density over the course of the 4-week-imaging period.
Thus, the lowered spine density observed near mature plaques
must result from a net spine loss at an earlier time point, probably
following initial plaque formation, after which spine density
stabilized again. This interpretation is supported by a recent study
in an APPPS1 mouse model, which showed that plaque deposition
precedes spine loss, and also found that even in aged APPPS1
mice, which already bear a substantial plaque load, spine density
in the vicinity of plaques does not differ from that seen in young
animals near plaques.16
Close to plaques, not only spine turnover was increased, but we
also found that particularly persistent spines, which are thought to
encode long-term memories,41,42 varied more strongly in size over
time. As spine size correlates with synapse strength,34,38,39 this
indicates that both, alterations in spine turnover as well as
ﬂuctuations in spine size, concertedly increase synaptic instability
close to plaques.
Notably, despite the fact that, on average, spines distant from
plaques did not behave differently from spines in WT mice, we
found evidence of altered structural plasticity independent of
Figure 3. g-secretase inhibitor (GSI) treatment reduces A generation in vivo and attenuates the deposition and growth of new plaques in
amyloid precursor protein/presenilin 1 (APPPS1) mice. (a) Representative western blot analysis of the effect of GSI application on full length
amyloid precursor protein (fl-APP) and APP C-terminal fragment (APP-CTF) levels in APPPS1 brain homogenates (blots of two different
experiments are shown). (b) Quantification of GSI effect on APP-CTFs normalized to fl-APP as measured in western blot (t-test, P¼ 0.0002). (c)
Quantification of ELISA analysis of soluble Ab species (Ab40 decreased by 66%, t-test, P¼ 0.036 and Ab42 decreased by 59%, t-test, P¼ 0.023,
vehicle n¼ 4, GSI n¼ 3 mice); open circles represent single data points, horizontal bars denote the mean and gray boxes the s.e.m. (d and e)
Examples of in vivo two-photon images in APPPS1 mice treated daily with vehicle (d) and 30mg kg 1 GSI (e), respectively. Images are
maximum projections of 50 optical sections (z-spacing 5 mm) over a depth of 250 mm. Red arrowheads indicate newly formed plaques, which
are marked with white arrowheads at consecutive imaging time points. (f ) Number of newly emerged plaques per standard ROI (350
350 285 mm) are lower in GSI-treated mice after the first week: one-sided Mann–Whitney test, P¼ 0.027, values are mean±s.e.m. (g) Plaques
newly formed within the first week of treatment are significantly smaller in GSI-treated mice (one-sided Mann–Whitney test, P¼ 0.014); black
lines denote the mean. (h) Newly formed plaques grow significantly slower in GSI compared with vehicle-treated mice; values are
median±95% confidence interval of the median (repeated measures ANOVA, P¼ 0.014; APP vehicle: 22 ROIs (five mice), 45 new plaques after
first week; APP GSI: 27 ROIs (seven mice), 31 new plaques after first week). Scale bar 20 mm, *Po0.05, ***Po0.001.
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plaque pathology. Whereas in WT mice spine density was
negatively correlated with spine turnover rate, as reported
previously,30 in APPPS1 mice dendrites further away from
plaques exhibited a positive correlation between spine density
and turnover rate. A more detailed analysis revealed that this
difference between genotypes was largely due to a reduced spine
turnover on low-density stretches in APPPS1 mice. The reduction
in spine dynamics on dendrites distant from plaques may indicate
a weakening of synaptic efﬁcacy. The induction of long-term
potentiation (LTP) on individual spines can promote the
potentiation of synapses on neighboring spines and the
formation of new adjacent spines, an effect known to spread
over several micrometers along the dendrite.46–50 In APP-
transgenic mice, soluble Ab is elevated within the interstitial
ﬂuid51 and is known to disrupt LTP induction and alter synapse
composition.52,53 This negative impact of Ab might impede
synaptic cooperativity, most prominently on dendrites bearing
only a few inputs, as their combined synaptic drive, and hence the
potential for ‘cross-talk’ between neighboring spines should be
lower even under physiological conditions.
In concert with the increased turnover rate of spines near
plaques, we also found that axonal boutons close to plaques were
less stable. In contrast to spine density, however, bouton density
did not change with plaque distance. Whereas this seems to be at
odds with histological studies showing a loss of presynaptic
markers close to plaques,17–19 the latter result likely reﬂects the
joint loss of axons (Supplementary Figure S5) and their boutons,
while we measure bouton density on those axons still present
close to plaques. Alternatively, the vulnerability of axonal boutons
to Ab/amyloid plaques may be cell type-speciﬁc. We have
conﬁned our analysis to intracortical axons of layer II/III/V neurons,
which have a lower bouton density and are more stable compared
with, for example, the axons of layer VI cells.33
The pathologically elevated dynamics of spines and boutons is
very likely to affect synaptic plasticity, and hence memory
formation, retention and retrieval, in a similar manner as the loss
of synapses. Recent imaging studies have shown that the
formation of long-term memories tightly correlates with the
emergence of long-lived spines in the cortex.41,42 On the other
hand, inherited forms of mental retardation, such as the fragile
X-syndrome, are associated with high spine turnover rates, as
observed in Fmr1 (fragile mental retardation 1) knockout mice.32,54
Moreover, altered dynamics of pre- and postsynaptic structures in
the cortex have recently been shown to accompany normal aging
Figure 4. Effect of g-secretase inhibitor (GSI) treatment on dendritic spines in amyloid precursor protein/presenilin 1 (APPPS1) mice. (a)
Example of dendritic spines in a GSI-treated APPPS1 mouse in the vicinity (o50 mm) of a plaque. The first imaging session was performed prior
to the start of treatment. Images are maximum projections. Open arrowheads indicate examples of spines lost between two consecutive
imaging time points, filled arrowheads mark spines that were gained. (b) Spine density is not affected by GSI treatment in APPPS1 mice
(repeated measures analysis of variance (ANOVA), P¼ 0.72). (c) The lower survival fraction (SF) of spines in the vicinity of plaques is normalized
by GSI treatment, thereby equaling the SF of spines distant from plaques in vehicle-treated mice (repeated measures ANOVA, Po0.01). (d) GSI
treatment increases the fraction of persistent spines near plaques (one-way ANOVA, Po0.05). Accordingly, the high fraction of transient spines
near plaques is reduced upon GSI treatment (one-way ANOVA, Po0.01). (e) Increased turnover of spines near plaques is reduced by the GSI
(one-way ANOVA, Po0.001). The effect is based on normalized (f ) elimination (one-way ANOVA, Po0.001) and (g) formation rates (Kruskal–
Wallis, Po0.01). APP distant veh: n¼ 21 dendrites (five mice); APP near veh: n¼ 12 dendrites (five mice); APP distant GSI: n¼ 32 dendrites
(seven mice); APP near GSI: n¼ 15 dendrites (seven mice). Values are mean±s.e.m, scale bar¼ 5 mm, *Po0.05, **Po0.01, ***Po0.001.
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and hence were suggested to underlie age-related cognitive
deﬁcits.55,56 Our ﬁnding of enhanced dynamics of synaptic
structures close to plaques resembles these changes observed
during normal ageing, alluding to potentially similar cellular
mechanisms causing the cognitive deﬁcits during normal aging
and AD. Together, these ﬁndings stress the causal relevance of
altered spine and bouton dynamics for neurodegenerative
diseases and, furthermore, imply that the impact of synaptic
instability on the cognitive decline seen in AD might have been
underestimated thus far.
The molecular mechanisms underlying the enhanced turnover
of synaptic structures close to plaques are not well understood.
Plaques are considered a reservoir of soluble Ab that seems to
extend with a gradient beyond the histological border of the dense
core plaque.6,10,12 This locally elevated concentration of soluble Ab
in the plaque region might cause the structural and functional
alterations predominantly seen in the vicinity of plaques, such as
dysmorphic neurites,26 changes in spine stability and spine
density,12,15,16 as well as the occurrence of clusters of hyperactive
cells and Ca2þ -overloaded dendrites.27,44 Spines on Ca2þ -
overloaded dendrites lack functional compartmentalization,27 a
property considered a prerequisite for synaptic integration.57,58 The
breakdown of spine compartmentalization in a subset of dendrites
near plaques might account for the observed spine instability.
In addition to plaques, other pathological events associated
with AD also affect synaptic structures. A recent in vivo imaging
study performed in triple transgenic AD mice (bearing in addition
to the APPswe and PS1M146V also the TauP301L mutation
59)
suggests that intraneuronal hyperphosphorylated tau can have a
strong impact on spine density as well.60 The authors describe
spine loss on dystrophic dendrites positive for hyperphos-
phorylated tau in brain areas that were devoid of plaques.
Figure 5. g-secretase inhibitor (GSI) effect on axonal boutons in amyloid precursor protein/presenilin 1 (APPPS1) mice. (a) Example of an
axonal stretch near a plaque in an APPPS1 mouse. (b) Bouton density is not affected by GSI treatment (Friedman’s test, P¼ 0.07). (c) The lower
survival fraction of boutons near plaques is normalized to levels observed distant from plaques (repeated measures analysis of variance
(ANOVA), APP distant vehicle versus APP near vehicle Po0.01, APP near vehicle versus APP near GSI Po0.001). (d) The increased turnover rate
of boutons near plaques is reduced after treatment; the effect did not reach significance (Kruskal–Wallis, APP near vehicle versus APP near GSI
P40.05). (e) Bouton lifetime fractions do not differ significantly between treated and untreated mice. APP distant veh: n¼ 14 axons (four
mice); APP near veh: n¼ 13 axons (four mice); APP distant GSI: n¼ 18 axons (seven mice); APP near GSI: n¼ 30 axons (seven mice). Values are
means±s.e.m., scale bar 10mm, *Po0.05, **Po0.01.
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Furthermore, in areas with substantial plaque load, spine density
was found to be lower even distant from plaques (450 mm).60
Having found that amyloid plaques cause local synaptic
instability, we next tested whether Ab-targeting treatment can
exert beneﬁcial effects on this pathology. At the concentration
used, the GSI, ELN594, inhibited g-secretase effectively, reducing
Ab generation in APPPS1 mice to levels comparable to those
observed with other GSIs in different APP-transgenic mice.22,61,62
We found that the lowered Ab levels caused an initial attenuation
of new plaque deposition and a sustained diminished growth of
the newly formed plaques throughout the treatment period, in
line with a previous report showing that GSI treatment can
suppress the formation of new plaques.21 The observed overall
decline in the number of newly formed plaques in the treatment
and control group might reﬂect the age dependency of de novo
plaque formation63 or could be attributable to the anti-
amyloidogenic properties of Methoxy-XO4,64 which we applied
repeatedly in order to label plaques in vivo. However, both the
vehicle- and the GSI-treated groups should be affected equally by
Methoxy-XO4, thus essentially resulting in a potential
underestimation of the GSI effect on plaque formation.
The moderate GSI effect on plaque pathology was accompanied
by a substantial impact on synaptic structures in the vicinity of
plaques. GSI treatment speciﬁcally reduced the plaque-associated
spine instability, resulting in spine turnover rates comparable to
those found in regions distal to plaques. Similarly, the GSI reduced
the increased size ﬂuctuations of persistent spines close to
plaques. Intriguingly, a more detailed analysis of the ‘near plaque’
spine cohort (o50 mm away) revealed that GSI treatment
normalized, in particular, the dynamics of spines located
415 mm away from the plaque border. As soluble Ab levels
gradually fall off next to dense core plaques,10 we propose that
the synapse-stabilizing effect of ELN594 occurs in a threshold-
dependent manner. We assume that the lower concentrations of
Ab at the periphery of the plaque-surrounding halo is cleared
more rapidly once additional Ab generation is inhibited via the
GSI, and as a consequence synaptic structures located there
recover from elevated turnover more readily than those still in
tight contact with the dense core plaque and higher Ab levels.
In a recent two-photon imaging study, GSI treatment was
shown to restore the pathologically enhanced neuronal-activity
levels in hippocampal CA1 neurons in predepositing APP-
transgenic mice.65 In depositing mice, however, hyperactive cells
are exclusively found within the vicinity of plaques both in the
hippocampus and the cortex.44,65 It remains to be clariﬁed
whether GSI treatment in depositing mice can prevent this
neuronal dysfunction in an equally effective manner as observed
in predepositing mice,65 which then would suggest a link between
our ﬁnding of GSI-induced synapse stabilization and the
normalization of neuronal-activity patterns near plaques.
We did not observe any effect of the GSI on dendrites distant
from plaques in APPPS1 mice nor on spines in WT mice. This is at
odds with a recently published study, which reported a GSI-
induced rapid and prolonged decrease in spine density in WT
mice after a short treatment period of 4 days.37 Earlier-generation
GSIs are known to non-selectively interfere with the processing of
other g-secretase substrates. In particular, impaired cleavage of
Notch, a cell-surface receptor involved in cell differentiation and
development,66 is thought to cause side effects of GSI treatment.
The inhibitors used in the above mentioned study, DAPT and
LY450139 (semagacestat), are unselective GSIs (ratio of EC50 values
for Notch and Ab42: DAPT¼ 0.5; LY450139¼ 0.867) and belong to
a different structural class than the second-generation compound
ELN594, a sulfonamide-type GSI with an at least 10-fold higher
selectivity of APP over Notch substrate cleavage (data not shown).
The previously investigated compounds might also substantially
differ in their pharmacokinetic and pharmacologic properties,
factors, which may further contribute to a different side effect
proﬁle. It is also conceivable that the compounds used in the
previous study might have had off-target effects. Chronic
administration of ELN594 on the other hand did not affect
dendritic spines or axonal boutons in WT mice or APPPS1 mice
distant from plaques and hence seems to be devoid of those
aforementioned side effects.
Taken together, we here for the ﬁrst time demonstrate in vivo
the ability of a GSI to selectively alleviate plaque-associated
synaptic pathology in a mouse model of AD. Given that the impact
of plaques on the density of spines has been shown in various
brain regions, such as neocortex and hippocampus,12,14–16 we
believe that the plaque-associated enhanced dynamics of synaptic
structures represents a general mechanism by which plaques
convey their detrimental effects on synapses. Thus, the GSI effect
on synapses should pertain to other brain regions as well. Our
data, moreover, argue in favor of the amyloid cascade hypothesis
and serve as a proof of principle regarding the efﬁcacy of
pharmacological interference with Ab generation.
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